This Pergoveris market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
The growth observed in the historic period can be attributed to several factors, including rising infertility rates, advancements in assisted reproductive technologies, increasing awareness about fertility treatments, growing healthcare expenditure, and delayed pregnancies due to lifestyle changes.
The growth anticipated in the forecast period can be attributed to factors such as technological innovations in fertility drugs, increasing adoption of IVF procedures, expanding healthcare access in emerging markets, the rising prevalence of hormonal disorders, and growing investment in reproductive health research. Key trends during this period include the integration of personalized medicine, the rise of combination drug therapies, a greater focus on patient-centric treatment plans, the use of advanced diagnostic tools for fertility, and the growth of telemedicine for fertility consultations.
The growing prevalence of infertility is expected to drive the expansion of the Pergoveris market. Infertility refers to the inability to conceive or carry a pregnancy to term, and it is becoming more widespread due to factors such as delayed childbearing, lifestyle choices, environmental toxins, and the rising occurrence of medical conditions such as polycystic ovary syndrome (PCOS) and endometriosis. Pergoveris helps address infertility by stimulating ovarian function through a combination of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), promoting egg development in women with severe gonadotropin deficiencies. According to the World Health Organization in April 2023, approximately 17.5% of the global adult population, or about one in six people, experience infertility. This increasing prevalence is driving the growth of the Pergoveris market.
The trend of delayed parenthood is also expected to contribute to the growth of the Pergoveris market. Factors such as increased career focus, higher education, financial considerations, and better access to reproductive technologies have led to more people choosing to delay having children. Pergoveris supports women who choose delayed parenthood by providing treatment for those with severe deficiencies in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), helping them stimulate follicular development and improve their chances of conception later in life. According to the United States Census Bureau in April 2022, fertility rates among women aged 20-24 decreased by 43% over the past 30 years, while fertility rates for women aged 35-39 increased by 67%. This shift toward delayed parenthood is driving the demand for Pergoveris.
The growing emphasis on reproductive health is expected to further boost the growth of the Pergoveris market. Increased attention to reproductive health is influenced by rising infertility rates, greater awareness of fertility issues, advancements in reproductive technologies, and the increasing importance placed on family planning and women's health. Pergoveris plays a role in reproductive health by helping women with infertility, especially those with low levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), by stimulating ovulation and supporting the development of mature eggs for fertilization. According to a report from gov.UK in February 2024, the use of long-acting reversible contraceptives (LARC) increased to 44.1 per 1,000 population in 2022-2023, up from 41.8 per 1,000 in the previous year. This growing focus on reproductive health will contribute to the growth of the Pergoveris market.
The key company operating in the pergoveris market is Merck KGaA.
Europe was the largest region in the pergoveris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pergoveris report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pergoveris market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Pergoveris is a biologic drug used in fertility treatments to stimulate ovarian function in women with severe gonadotropin deficiency, a condition where the body produces inadequate amounts of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). It combines recombinant FSH and LH, which are essential for stimulating the ovaries to produce mature eggs for assisted reproductive technologies (ART) such as in vitro fertilization (IVF). Pergoveris supports follicular growth and ovulation in women undergoing fertility treatments.
The primary formulations of Pergoveris include an injectable pen and a vial formulation. The Pergoveris injectable pen is a device used to administer the combination of recombinant FSH and LH for fertility treatments. Its indications include anovulation and ART procedures, with distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies. The product is used in various settings, including hospitals, clinics, ambulatory care, and home care.
The pergoveris market research report is one of a series of new reports that provides pergoveris market statistics, including pergoveris industry global market size, regional shares, competitors with a pergoveris market share, detailed pergoveris market segments, market trends, and opportunities, and any further data you may need to thrive in the pergoveris industry. This pergoveris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pergoveris market consists of sales of pergoveris 150 IU/75 IU, pergoveris 300 IU/150 IU, and pre-filled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth observed in the historic period can be attributed to several factors, including rising infertility rates, advancements in assisted reproductive technologies, increasing awareness about fertility treatments, growing healthcare expenditure, and delayed pregnancies due to lifestyle changes.
The growth anticipated in the forecast period can be attributed to factors such as technological innovations in fertility drugs, increasing adoption of IVF procedures, expanding healthcare access in emerging markets, the rising prevalence of hormonal disorders, and growing investment in reproductive health research. Key trends during this period include the integration of personalized medicine, the rise of combination drug therapies, a greater focus on patient-centric treatment plans, the use of advanced diagnostic tools for fertility, and the growth of telemedicine for fertility consultations.
The growing prevalence of infertility is expected to drive the expansion of the Pergoveris market. Infertility refers to the inability to conceive or carry a pregnancy to term, and it is becoming more widespread due to factors such as delayed childbearing, lifestyle choices, environmental toxins, and the rising occurrence of medical conditions such as polycystic ovary syndrome (PCOS) and endometriosis. Pergoveris helps address infertility by stimulating ovarian function through a combination of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), promoting egg development in women with severe gonadotropin deficiencies. According to the World Health Organization in April 2023, approximately 17.5% of the global adult population, or about one in six people, experience infertility. This increasing prevalence is driving the growth of the Pergoveris market.
The trend of delayed parenthood is also expected to contribute to the growth of the Pergoveris market. Factors such as increased career focus, higher education, financial considerations, and better access to reproductive technologies have led to more people choosing to delay having children. Pergoveris supports women who choose delayed parenthood by providing treatment for those with severe deficiencies in luteinizing hormone (LH) and follicle-stimulating hormone (FSH), helping them stimulate follicular development and improve their chances of conception later in life. According to the United States Census Bureau in April 2022, fertility rates among women aged 20-24 decreased by 43% over the past 30 years, while fertility rates for women aged 35-39 increased by 67%. This shift toward delayed parenthood is driving the demand for Pergoveris.
The growing emphasis on reproductive health is expected to further boost the growth of the Pergoveris market. Increased attention to reproductive health is influenced by rising infertility rates, greater awareness of fertility issues, advancements in reproductive technologies, and the increasing importance placed on family planning and women's health. Pergoveris plays a role in reproductive health by helping women with infertility, especially those with low levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), by stimulating ovulation and supporting the development of mature eggs for fertilization. According to a report from gov.UK in February 2024, the use of long-acting reversible contraceptives (LARC) increased to 44.1 per 1,000 population in 2022-2023, up from 41.8 per 1,000 in the previous year. This growing focus on reproductive health will contribute to the growth of the Pergoveris market.
The key company operating in the pergoveris market is Merck KGaA.
Europe was the largest region in the pergoveris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pergoveris report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pergoveris market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Pergoveris is a biologic drug used in fertility treatments to stimulate ovarian function in women with severe gonadotropin deficiency, a condition where the body produces inadequate amounts of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). It combines recombinant FSH and LH, which are essential for stimulating the ovaries to produce mature eggs for assisted reproductive technologies (ART) such as in vitro fertilization (IVF). Pergoveris supports follicular growth and ovulation in women undergoing fertility treatments.
The primary formulations of Pergoveris include an injectable pen and a vial formulation. The Pergoveris injectable pen is a device used to administer the combination of recombinant FSH and LH for fertility treatments. Its indications include anovulation and ART procedures, with distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies. The product is used in various settings, including hospitals, clinics, ambulatory care, and home care.
The pergoveris market research report is one of a series of new reports that provides pergoveris market statistics, including pergoveris industry global market size, regional shares, competitors with a pergoveris market share, detailed pergoveris market segments, market trends, and opportunities, and any further data you may need to thrive in the pergoveris industry. This pergoveris market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The pergoveris market consists of sales of pergoveris 150 IU/75 IU, pergoveris 300 IU/150 IU, and pre-filled syringes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Pergoveris Market Characteristics4. Pergoveris Market Trends and Strategies5. Pergoveris Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Pergoveris Pricing Analysis & Forecasts30. Global Pergoveris Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Pergoveris Market32. Recent Developments in the Pergoveris Market
3. Pergoveris Market Biologic Drug Characteristics
6. Global Pergoveris Growth Analysis and Strategic Analysis Framework
8. Pergoveris Market Segmentation
9. Global Pergoveris Epidemiology of Clinical Indications
10. Pergoveris Market Regional and Country Analysis
11. Asia-Pacific Pergoveris Market
12. China Pergoveris Market
13. India Pergoveris Market
14. Japan Pergoveris Market
15. Australia Pergoveris Market
16. South Korea Pergoveris Market
17. Western Europe Pergoveris Market
18. UK Pergoveris Market
19. Germany Pergoveris Market
20. France Pergoveris Market
21. Eastern Europe Pergoveris Market
22. North America Pergoveris Market
23. USA Pergoveris Market
24. Canada Pergoveris Market
25. South America Pergoveris Market
26. Middle East Pergoveris Market
27. Africa Pergoveris Market
28. Pergoveris Market Competitive Landscape and Company Profiles
29. Global Pergoveris Market Pipeline Analysis
33. Pergoveris Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Pergoveris Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on pergoveris market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for pergoveris? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pergoveris market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Formulation: Injectable Pen; Vial Formulation2) by Indication: Anovulation; Assisted Reproductive Technology (ART) Procedures
3) by Distribution Channel: Hospitals Pharmacies; Retail Pharmacies; Online Pharmacies
4) by End Use: Hospitals; Clinics; Ambulatory Care; Home Care
Key Companies Mentioned: Merck KGaA
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Merck KGaA
